Innovative Cellular Therapeutics (Global Rights of CAR T-Cell Candidate for Colorectal Cancer) Overview
- Status
-
Acquired/Merged
- Latest Deal Type
-
Asset Purch.
- Financing Rounds
-
1
Innovative Cellular Therapeutics (Global Rights of CAR T-Cell Candidate for Colorectal Cancer) General Information
Description
Global rights of cell expansion, immune cell infiltration, and cancer cell killing product candidate used for metastatic colorectal cancer.
Contact Information
Corporate Office
- Rockville, MD
- United States
Corporate Office
- Rockville, MD
- United States
Innovative Cellular Therapeutics (Global Rights of CAR T-Cell Candidate for Colorectal Cancer) Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Innovative Cellular Therapeutics (Global Rights of CAR T-Cell Candidate for Colorectal Cancer) Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Innovative Cellular Therapeutics (Global Rights of CAR T-Cell Candidate for Colorectal Cancer) FAQs
-
Where is Innovative Cellular Therapeutics (Global Rights of CAR T-Cell Candidate for Colorectal Cancer) headquartered?
Innovative Cellular Therapeutics (Global Rights of CAR T-Cell Candidate for Colorectal Cancer) is headquartered in Rockville, MD.
-
What industry is Innovative Cellular Therapeutics (Global Rights of CAR T-Cell Candidate for Colorectal Cancer) in?
Innovative Cellular Therapeutics (Global Rights of CAR T-Cell Candidate for Colorectal Cancer)’s primary industry is Buildings and Property.
-
Is Innovative Cellular Therapeutics (Global Rights of CAR T-Cell Candidate for Colorectal Cancer) a private or public company?
Innovative Cellular Therapeutics (Global Rights of CAR T-Cell Candidate for Colorectal Cancer) is a Private company.
-
What is the current valuation of Innovative Cellular Therapeutics (Global Rights of CAR T-Cell Candidate for Colorectal Cancer)?
The current valuation of Innovative Cellular Therapeutics (Global Rights of CAR T-Cell Candidate for Colorectal Cancer) is .
-
What is Innovative Cellular Therapeutics (Global Rights of CAR T-Cell Candidate for Colorectal Cancer)’s current revenue?
The current revenue for Innovative Cellular Therapeutics (Global Rights of CAR T-Cell Candidate for Colorectal Cancer) is .
-
Who are Innovative Cellular Therapeutics (Global Rights of CAR T-Cell Candidate for Colorectal Cancer)’s investors?
Innovative Cellular Therapeutics has invested in Innovative Cellular Therapeutics (Global Rights of CAR T-Cell Candidate for Colorectal Cancer).
-
When was Innovative Cellular Therapeutics (Global Rights of CAR T-Cell Candidate for Colorectal Cancer) acquired?
Innovative Cellular Therapeutics (Global Rights of CAR T-Cell Candidate for Colorectal Cancer) was acquired on 10-Nov-2025.
-
Who acquired Innovative Cellular Therapeutics (Global Rights of CAR T-Cell Candidate for Colorectal Cancer)?
Innovative Cellular Therapeutics (Global Rights of CAR T-Cell Candidate for Colorectal Cancer) was acquired by Lyell Immunopharma.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process